Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine Mechanism in Acquired Brain Injury
NCT02566720Unknown
- Sponsor
- Hamilton Health Sciences
- Start
- Jan 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amantadine in acquired brain injury (ABI), Persistent Vegetative State (PVS) and Minimally conscious state (MCS), sponsored by Hamilton Health Sciences. Primary endpoint: Size of RAS tracts as measured by MRI tractography at 90 days. Status: unknown.
02
Drugs
amantadine
03
Conditions
acquired brain injury (ABI)Persistent Vegetative State (PVS)Minimally conscious state (MCS)
Beyond the preview
Go deeper on NCT02566720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566720.